Evidence map›Paper›PMID 26955235›Full record

ArticleJournal of Korean medical science2016

Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.

Min-Jung Kim, Jeong-Eun Koo, Gi-Yeon Han, Buyun Kim, Yoo-Sun Lee, Chiyoung Ahn, Chan-Wha Kim

Open access · goldAbstract read
In one paragraph

Article in Journal of Korean medical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Min-Jung KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea.; Ministry of Food and Drug Safety, Cheongju, Korea.ORCID 0000-0002-5544-8676
Jeong-Eun KooDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea .ORCID 0000-0001-6733-2518
Gi-Yeon HanDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea .ORCID 0000-0001-9825-169X
Buyun KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea .
Yoo-Sun LeeDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea .ORCID 0000-0002-2258-6749
Chiyoung AhnMinistry of Food and Drug Safety, Cheongju, Korea .ORCID 0000-0002-3747-0175
Chan-Wha KimDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea .ORCID 0000-0003-2329-8834
Korea University · KRMinistry of Food and Drug Safety · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) have tumor initiation, self-renewal, metastasis and chemo-resistance properties in various tumors including colorectal cancer. Targeting of CSCs may be essential to prevent relapse of tumors after chemotherapy. Phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signals are central regulators of cell growth, proliferation, differentiation, and apoptosis. These pathways are related to colorectal tumorigenesis. This study focused on PI3K and mTOR pathways by inhibition which initiate differentiation of SW620 derived CSCs and investigated its effect on tumor progression. By using rapamycin, LY294002, and NVP-BEZ235, respectively, PI3K and mTOR signals were blocked independently or dually in colorectal CSCs. Colorectal CSCs gained their differentiation property and lost their stemness properties most significantly in dual-blocked CSCs. After treated with anti-cancer drug (paclitaxel) on the differentiated CSCs cell viability, self-renewal ability and differentiation status were analyzed. As a result dual-blocking group has most enhanced sensitivity for anti-cancer drug. Xenograft tumorigenesis assay by using immunodeficiency mice also shows that dual-inhibited group more effectively increased drug sensitivity and suppressed tumor growth compared to single-inhibited groups. Therefore it could have potent anti-cancer effects that dual-blocking of PI3K and mTOR induces differentiation and improves chemotherapeutic effects on SW620 human colorectal CSCs.

Indexed as

Phosphoinositide-3 Kinase InhibitorsAC133 AntigenAnimalsAntineoplastic AgentsCell DifferentiationCell Line, TumorCell SurvivalChromonesColorectal NeoplasmsHumansImidazolesMaleMiceMice, Inbred BALB CMice, NudeMorpholines2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAC133 AntigenAntineoplastic AgentsChromonesdactolisibImidazolesMorpholinesMTOR protein, humanPaclitaxelPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsQuinolinesSirolimusSOX2 protein, humanSOXB1 Transcription FactorsTOR Serine-Threonine KinasesCancer Stem CellsDifferentiation TherapyDrug ResistancemTORPI3K

Identifiers

PMID26955235
PMCPMC4779859
OpenAlexW2285780854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.